Inmune Bio, Inc. (INMB)
About Inmune Bio, Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $50.0K
- Net income
- -$45.9M
- Total assets
- $32.4M
- Market cap
- $33.5M
- Operating margin
- -94766.0%
- Net margin
- -91866.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $50.0K
- Operating expenses
- $47.4M
- Operating income
- -$47.4M
- Net income
- -$45.9M
- EPS (basic)
- $-1.86
- EPS (diluted)
- $-1.86
Balance sheet
- Total assets
- $32.4M
- Current assets
- $29.9M
- Total liabilities
- $8.8M
- Current liabilities
- $8.4M
- Shareholders’ equity
- $23.5M
Cash flow
- Operating cash flow
- -$22.6M
- Investing cash flow
- -$4.9M
- Financing cash flow
- $27.6M
- Net cash flow
- $159.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $33.5M
- EPS (diluted)
- $-1.86
- Shares outstanding
- 20.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 4, 2019
Inmune Bio, Inc. (INMB) Stock Price
- Reported a net loss of $45.9M in FY2025.
- Revenue declined 72% from FY2021 to FY2025.
- Trading 78% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inmune Bio, Inc..
Write a review
News about Inmune Bio, Inc.
News & sentiment via Polygon.io
Inmune Bio, Inc.: frequently asked questions
Is Inmune Bio, Inc. an American company?
Inmune Bio, Inc. is a US-based company headquartered in Boca Raton, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Inmune Bio, Inc. headquartered?
Inmune Bio, Inc. is headquartered in Boca Raton, Florida, United States.
Is Inmune Bio, Inc. publicly traded?
Yes — Inmune Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol INMB on the NASDAQ.
What does Inmune Bio, Inc. do?
Inmune Bio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
